Clinical Trials Logo

Filter by:
NCT ID: NCT06267976 Recruiting - Healthy Clinical Trials

Validation of the ProSomnus® RPMO2 Device

Start date: June 15, 2024
Phase:
Study type: Observational

The purpose of the study is to: 1. Evaluate the SpO2 accuracy of the oximeter component of the ProSomnus RPMO2 Device during non-motion conditions over the range of 70-100% SaO2 by comparison to SaO2 values determined by arterial blood sample specimen analyzed by a CO-oximeter. 2. Evaluate the pulse rate performance simultaneously collected over the SpO2 range.

NCT ID: NCT06267482 Recruiting - Knee Osteoarthritis Clinical Trials

Using ROSA for Challenging The TKA Standard of Care

Start date: April 16, 2024
Phase: Phase 4
Study type: Interventional

This is a prospective, randomized controlled trial using the cruciate retaining, MC Persona to comparing the conventional TKA to ROSA assisted TKA. Patients will be randomized to one of three study trial arms. 1. Standard of care medial parapetallar approach (Control) 2. ROSA PSA medial parapetallar approach 3. ROSA PSA medial subvastus approach Participants will be followed for 1 year post surgery with a combination of perioperative parameters, imaging, patient reported outcomes, functional outcomes, blood and tissue sampling for inflammatory information and activity levels.

NCT ID: NCT06266442 Recruiting - Clinical trials for Respiratory Tract Diseases

M. Avium WGS During Mav-PD Treatment

Start date: May 13, 2024
Phase:
Study type: Observational

This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto/York region versus participants living elsewhere. The primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection.

NCT ID: NCT06264141 Recruiting - Clinical trials for Recurrent Acute Rhinosinusitis

Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis

NONS-RARS-01
Start date: January 16, 2024
Phase: Phase 2
Study type: Interventional

A two-week therapy of nitric oxide nasal spray (NONS) vs Placebo (saline nasal spray) initiated immediately after the onset of a new Recurrent Acute Rhinosinusitis (RARS) episode to assess the acceleration to clinical success (cured/much improved symptoms), lack of use of intranasal corticosteroids (INCS) (Day 5, or thereafter) and rescue oral antibiotics (ATBs) (Day 8, or thereafter) after initiation of nitric oxide releasing solution (NORS) platform therapy.

NCT ID: NCT06262594 Recruiting - Epilepsy Clinical Trials

Lemborexant Treatment of Insomnia Linked to Epilepsy

L'ÉTOILE
Start date: April 18, 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.

NCT ID: NCT06261957 Recruiting - Asthma Clinical Trials

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma

Start date: May 31, 2024
Phase: Phase 3
Study type: Interventional

The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged 12 years and above with asthma.

NCT ID: NCT06261424 Recruiting - Clinical trials for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay

Effects of a Supervised Rehabilitation Program on Disease Severity in Spastic Ataxias

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

Spastic ataxias are a group of diseases causing symptoms such as walking difficulties and balance impairments that lead to a high risk of falls. No pharmacological treatments exist to treat these diseases. Unfortunately, little effort is made to develop non-pharmacological treatments specific to spastic ataxias despite the detrimental impact of the disease on several aspects of an individual's life and the high cost of falls for society each year. The three objectives of this project are: 1) to determine the effect of a 12-week rehabilitation program on disease severity as compared with usual care for individuals with spastic ataxias; 2) to identify which factors can help (or not) the implementation of the program in the clinical settings ("reel world"); and 3) to explore the cost-benefits of IMPACT [rehabIlitation prograM for sPAstiC aTaxias]. The team has developed the program to specifically target symptoms present in these patients and was previously pilot-tested. Based on the results obtained in this pilot project, positive effects are expected concerning the disease severity of participants. The investigators want, with this project, provide to health care professionals an option to offer better-suited services to people living with spastic ataxia worldwide.

NCT ID: NCT06261021 Recruiting - Clinical trials for Discoid Lupus Erythematosus

Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects With Discoid Lupus Erythematosus

Start date: April 19, 2024
Phase: Phase 2
Study type: Interventional

This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.

NCT ID: NCT06260735 Recruiting - Clinical trials for Spinal Cord Injuries

Non-invasive Spinal Cord Stimulation After Spinal Cord Injury

SCI-ES-WALK
Start date: June 15, 2023
Phase: N/A
Study type: Interventional

Spinal cord injury (SCI) is a central nervous system injury that often leads to motor dysfunction. Non-invasive electrical stimulation of the spinal cord has been recognized as a potential method of reactivating lost spinal neural networks to improve motor recovery and exercise response after SCI. Trans-spinal electrical stimulation (ts-ES) has been found to increase functional gains in people after SCI when applied in combination with other motor training protocols. This project aims to evaluate the effects of non-invasive lumbar spinal cord electrical stimulation on the motor function of trunk and lower limbs in people with SCI after augmenting their locomotor training (treadmill stepping) with step-cycle-based electrical peripheral neural stimulation methods.

NCT ID: NCT06260722 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Start date: February 21, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.